ENVB vs. GDTC, BIOR, COCP, BFRG, SLGL, FBRX, CPIX, JAGX, IBIO, and PPBT
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include CytoMed Therapeutics (GDTC), Biora Therapeutics (BIOR), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), Cumberland Pharmaceuticals (CPIX), Jaguar Health (JAGX), iBio (IBIO), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical preparations" industry.
Enveric Biosciences (NASDAQ:ENVB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Enveric Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 1,182.05%. CytoMed Therapeutics has a consensus target price of $5.00, indicating a potential upside of 131.48%. Given Enveric Biosciences' higher probable upside, analysts plainly believe Enveric Biosciences is more favorable than CytoMed Therapeutics.
13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 1.2% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
CytoMed Therapeutics' return on equity of 0.00% beat Enveric Biosciences' return on equity.
In the previous week, Enveric Biosciences had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Enveric Biosciences and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.44 beat Enveric Biosciences' score of 0.46 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.
Enveric Biosciences received 3 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote.
Summary
Enveric Biosciences and CytoMed Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
